文献速递生殖医学

整合倍性与常见致病性微缺失分析提高植入前遗传学检测的临床效用

Improved clinical utility of preimplantation genetic testing through the integration of ploidy and common pathogenic microdeletions analyses.
PubMed 文献 · Hum Reprod · 2023-01-01

该回顾性队列分析纳入2018年2月至2021年11月多家IVF诊所的囊胚活检样本,开发了一种基于靶向二代测序和概率模型的平台,可同时评估倍性水平和九种常见致病性微缺失。在临床应用中,于100枚标准PGT-A判定为整倍体的囊胚中检出1例三倍体,于99枚导致妊娠丢失的整倍体胚胎活检样本中回顾性检出1例-22q11.21微缺失,估计整倍体胚胎中非整倍体倍性异常和/或微缺失的发生率为1.5%(n=3/202,95%CI:0.5-4.5%)。

要点

  • 该整合方法在倍性分类上准确率为100%(CI:98.1-100%),在8种微缺失中识别6种的准确率为99.2%(CI:98.5-99.8%)。
  • 临床应用中,100枚标准PGT-A整倍体囊胚中检出1例三倍体;99枚妊娠丢失的整倍体胚胎中回顾性检出1例-22q11.21微缺失。
  • 整倍体胚胎中倍性异常和/或微缺失的估计发生率为1.5%(n=3/202,95%CI:0.5-4.5%)。

核心结论

  • 所提出的整合方法能准确评估倍性水平和导致基因组病的常见致病性微缺失,扩展了PGT的临床效用。

研究设计与样本

  • 回顾性队列分析,纳入2018年2月至2021年11月多家合作的IVF诊所采集的囊胚活检样本,对象为45岁以下欧洲血统、使用自体配子且所有卵母细胞行ICSI的准父母。
  • 倍性水平判定用164例已知倍性状态的胚胎样本验证(147例二倍体、9例三倍体、8例单倍体);九种常见微缺失综合征的检测用28例阳性对照和97例阴性对照开发和测试。
  • 方法学基于全基因组所选多态性的靶向二代测序,测序数据(等位基因频率)通过概率模型分析,该模型估计倍性水平和微缺失存在的可能性,并考虑测序噪声和群体遗传学模式(如连锁不平衡相关性),参考1000 Genome Project数据库的2504份全基因组测序数据。
  • 通过SNP阵列基因分型获得的父母单体型分析用于确认微缺失的存在。

主要发现

  • 分析验证阶段,倍性分类准确率为100%(CI:98.1-100%),8种微缺失中6种的识别准确率为99.2%(CI:98.5-99.8%)。
  • 因可靠性差,chr1p36和chr4p16.3区域被排除在微缺失识别之外,并开发了纳入父母DNA信息的临床工作流程以增强微缺失识别。
  • 临床应用阶段,在100枚2PN来源的囊胚中检出1例三倍体。
  • 在99枚导致妊娠丢失的整倍体胚胎活检样本中回顾性检出1例致病性微缺失(-22q11.21);该病例的家庭分析显示,非携带者父母的不同同胞胚胎(n=2/5)中存在相同微缺失,提示女性伴侣存在生殖系嵌合。
  • 当根据遗传组成选择胚胎移植时,该策略可识别具有非整倍体以外倍性异常和/或微缺失的胚胎,估计在整倍体胚胎中的发生率为1.5%(n=3/202,95%CI:0.5-4.5%)。

临床怎么用

  • 作者指出,该策略可在移植前识别具有倍性异常和/或非整倍体以外微缺失的胚胎。
  • 作者指出,该新型检测通过整合导致基因组病的最常见致病性微缺失(包括新发和遗传性),显著扩展了PGT-A的临床效用,这些微缺失通常通过侵入性产前检测在较晚阶段评估。

局限性

  • 需要流行病学研究来准确评估植入前胚胎中倍性改变和微缺失的发生率,尤其是整倍体流产中的发生率。
  • 尽管所开发检测准确度高,但使用父母DNA支持诊断判定可进一步提高检测精度。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

STUDY QUESTION: Can chromosomal abnormalities beyond copy-number aneuploidies (i.e. ploidy level and microdeletions (MDs)) be detected using a preimplantation genetic testing (PGT) platform? SUMMARY ANSWER: The proposed integrated approach accurately assesses ploidy level and the most common pathogenic microdeletions causative of genomic disorders, expanding the clinical utility of PGT. WHAT IS KNOWN ALREADY: Standard methodologies employed in preimplantation genetic testing for aneuploidy (PGT-A) identify chromosomal aneuploidies but cannot determine ploidy level nor the presence of recurrent pathogenic MDs responsible for genomic disorders. Transferring embryos carrying these abnormalities can result in miscarriage, molar pregnancy, and intellectual disabilities and developmental delay in offspring. The development of a testing strategy that integrates their assessment can resolve current limitations and add valuable information regarding the genetic constitution of embryos, which is not evaluated in PGT providing new level of clinical utility and valuable knowledge for further understanding of the genomic causes of implantation failure and early pregnancy loss. To the best of our knowledge, MDs have never been studied in preimplantation human embryos up to date. STUDY DESIGN, SIZE, DURATION: This is a retrospective cohort analysis including blastocyst biopsies collected between February 2018 and November 2021 at multiple collaborating IVF clinics from prospective parents of European ancestry below the age of 45, using autologous gametes and undergoing ICSI for all oocytes. Ploidy level determination was validated using 164 embryonic samples of known ploidy status (147 diploids, 9 triploids, and 8 haploids). Detection of nine common MD syndromes (-4p=Wolf-Hirschhorn, -8q=Langer-Giedion, -1p=1p36 deletion, -22q=DiGeorge, -5p=Cri-du-Chat, -15q=Prader-Willi/Angelman, -11q=Jacobsen, -17p=Smith-Magenis) was developed and tested using 28 positive controls and 97 negative controls. Later, the methodology was blindly applied in the analysis of: (i) 100 two pronuclei (2PN)-derived blastocysts that were previously defined as uniformly euploid by standard PGT-A; (ii) 99 euploid embryos whose transfer resulted in pregnancy loss. PARTICIPANTS/MATERIALS, SETTING, METHODS: The methodology is based on targeted next-generation sequencing of selected polymorphisms across the genome and enriched within critical regions of included MD syndromes. Sequencing data (i.e. allelic frequencies) were analyzed by a probabilistic model which estimated the likelihood of ploidy level and MD presence, accounting for both sequencing noise and population genetics patterns (i.e. linkage disequilibrium, LD, correlations) observed in 2504 whole-genome sequencing data from the 1000 Genome Project database. Analysis of phased parental haplotypes obtained by single-nucleotide polymorphism (SNP)-array genotyping was performed to confirm the presence of MD. MAIN RESULTS AND THE ROLE OF CHANCE: In the analytical validation phase, this strategy showed extremely high accuracy both in ploidy classification (100%, CI: 98.1-100%) and in the identification of six out of eight MDs (99.2%, CI: 98.5-99.8%). To improve MD detection based on loss of heterozygosity (LOH), common haploblocks were analyzed based on haplotype frequency and LOH occurrence in a reference population, thus developing two further mathematical models. As a result, chr1p36 and chr4p16.3 regions were excluded from MD identification due to their poor reliability, whilst a clinical workflow which incorporated parental DNA information was developed to enhance the identification of MDs. During the clinical application phase, one case of triploidy was detected among 2PN-derived blastocysts (i) and one pathogenic MD (-22q11.21) was retrospectively identified among the biopsy specimens of transferred embryos that resulted in miscarriage (ii). For the latter case, family-based analysis revealed the same MD in different sibling embryos (n = 2/5) from non-carrier parents, suggesting the presence of germline mosaicism in the female partner. When embryos are selected for transfer based on their genetic constitution, this strategy can identify embryos with ploidy abnormalities and/or MDs beyond aneuploidies, with an estimated incidence of 1.5% (n = 3/202, 95% CI: 0.5-4.5%) among euploid embryos. LIMITATIONS, REASONS FOR CAUTION: Epidemiological studies will be required to accurately assess the incidence of ploidy alterations and MDs in preimplantation embryos and particularly in euploid miscarriages. Despite the high accuracy of the assay developed, the use of parental DNA to support diagnostic calling can further increase the precision of the assay. WIDER IMPLICATIONS OF THE FINDINGS: This novel assay significantly expands the clinical utility of PGT-A by integrating the most common pathogenic MDs (both de novo and inherited ones) responsible for genomic disorders, which are usually evaluated at a later stage through invasive prenatal testing. From a basic research standpoint, this approach will help to elucidate fundamental biological and clinical questions related to the genetics of implantation failure and pregnancy loss of otherwise euploid embryos. STUDY FUNDING/COMPETING INTEREST(S): No external funding was used for this study. S.C., M.F., F.C., P.Z., I.P., L.G., C.P., M.P., D.B., J.J.-A., D.B.-J., J.M.-V., and C.R. are employees of Igenomix and C.S. is the head of the scientific board of Igenomix. A.C. and L.P. are employees of JUNO GENETICS. Igenomix and JUNO GENETICS are companies providing reproductive genetic services. TRIAL REGISTRATION NUMBER: N/A.

来源:Hum Reprod,查看原文。版权归原作者所有。

引用

  1. Caroselli S, Figliuzzi M, Picchetta L, et al. Improved clinical utility of preimplantation genetic testing through the integration of ploidy and common pathogenic microdeletions analyses. Hum Reprod. 2023. PMID: 36824049. doi:10.1093/humrep/dead033

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。